Global Oncology Industry Market Research & Statistics

Pancreatic Cancer: Opportunity Analysis and Forecast to ... $ 10995 April 2018

Pancreatic Cancer: Opportunity Analysis and Forecast to 2026SummaryPancreatic cancer is set to become the second leading cause of cancer-related deaths in the US in 2020 after lung cancer, despite accounting ...

PharmaPoint: Prostate Cancer - Global Drug Forecast and ... $ 10995 November 2017

PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2026SummaryProstate cancer (PCa) is the second most common cancer in men worldwide, after skin cancer. It accounts for 12% of ...

PharmaPoint: Macular Edema - Global Drug Forecast and M ... $ 10995 November 2017

PharmaPoint: Macular Edema - Global Drug Forecast and Market Analysis to 2026SummaryMacular edema (ME) is a condition where fluid and protein deposits accumulate on the macula, causing it to swell, leading ...

PharmaPoint: Melanoma - Global Drug Forecast and Market ... $ 10995 September 2017

PharmaPoint: Melanoma - Global Drug Forecast and Market Analysis to 2026SummaryMelanoma is the deadliest and most aggressive form of skin cancer. Melanoma is rare compared to other major cancer indications, ...

OpportunityAnalyzer: Acute Myeloid Leukemia - Opportuni ... $ 10995 July 2017

OpportunityAnalyzer: Acute Myeloid Leukemia - Opportunity Analysis and Forecasts to 2026SummaryAcute myeloid leukemia (AML) is a rapidly progressing blood cancer with a poor overall prognosis. AML is relatively ...

PharmaPoint: HER2-Positive Breast Cancer - Global Drug ... $ 10995 June 2017

PharmaPoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2025SummaryHER2-positive breast cancer is the second most common cancer in the world and the most common cancer in ...

Drug Analysis: Ofatumumab $ 10000 November 2017

Drug OverviewOfatumumab (Genmab/Novartis) is a fully human immunoglobulin G1 and high-affinity antibody that targets a novel epitope on cluster of differentiation (CD)20 on the B-cell membrane. Ofatumuma ...

Targeted Therapies in Asthma: KOL Insight [2018] $ 8685 February 2018

Can new biologics breathe fresh competition into the targeted asthma treatment landscape?The severe asthma treatment landscape is evolving. Near-term debates will focus on how best to use currently approved ...

Market Access, Pricing and Reimbursement of Oncology Me ... $ 7995 September 2018

Market Access, Pricing and Reimbursement of Oncology Medicines in the 5EUSummaryMarket access of oncology medicines is increasingly challenging due to the rising cost of new and innovative medicines, more ...